An analyst recommends buying SpaceX stock at its IPO, highlighting five key reasons including Starlink's 49.8% year-over-year revenue growth and doubling of subscribers to 10.3 million. Despite a $4.94 billion net loss in 2025 due to $20.7 billion capital expenditure mainly in AI, the company's growth potential is strong. The IPO could trade above 90 times sales, which is high but reflects investor enthusiasm. Investors are advised to allocate only 1-3% of their portfolio to SpaceX and watch for execution risks, especially with the expected inclusion in the S&P 500 index.
Calidi Biotherapeutics announced that its 2025 Annual Report included an audit report with an explanatory paragraph highlighting the assumption that the company will continue as a going concern. This disclosure is mandated by the NYSE American Compan...
Silvercorp Metals Inc. announced a semi-annual dividend of US$0.0125 per share, payable to shareholders of record on June 5, 2026, with payment scheduled by June 25, 2026. The dividend is eligible for Canadian tax purposes. The company, a Canadian mi...
Oura Health is preparing for an IPO that could indicate whether public markets are ready to support consumer-focused digital health companies. Unlike earlier wearables focused on hardware sales, Oura emphasizes a subscription model offering health in...
Richmond Mutual Bancorporation, a community-focused bank holding company based in Indiana, announced a quarterly cash dividend of $0.15 per share. The dividend will be paid on June 17, 2026, to shareholders recorded as of June 3, 2026. This dividend ...
Zimmer Biomet Holdings, a global leader in medical technology, announced a quarterly cash dividend of $0.24 per share for the second quarter of 2026. The dividend will be paid on or about July 31, 2026, to shareholders of record as of June 25, 2026. ...
